Real world data (RWD) are no substitute for a well-run randomized clinical trial, but they can help developers, regulators and clinicians better understand patients and how a drug candidate stands to impact patient care. In this report, Clarivate examines how drug companies are using RWD sources such as claims, EHR/EMR and registry data to better understand patients, conditions, and how drug candidates stand to impact patient care.
In this report, Clarivate examines how drug developers are using RWD to shape, supplement, enhance and accelerate their clinical trials, including:
- Identifying underserved populations and understanding which patient groups stand to benefit most from new treatments.
- Enabling targeted site and investigator selection to ensure successful and expeditious trial completion.
- Making clinical trials more representative of real world patient populations.
- Anticipating patient unmet needs and barriers to treatment.
Download the full report to learn more.
